U S Physical Therapy Inc: Form 10-Q for the period ended Jun 30, 2017
Filed with the SEC on Aug 7, 2017 and accepted by EDGAR at Aug 7, 2017, 14:36 ET.
Management's discussion and analysis
As filed, 41,977 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The following is a discussion of our historical consolidated financial condition and results of operations, and should be read in conjunction with (i) our historical consolidated financial statements and accompanying notes thereto included elsewhere in this Quarterly Report on Form 10-Q; (ii) our Annual Report on Form 10-K for the year ended December 31, 2016 filed with the Securities and Exchange Commission (the “SEC”) on June 07, 2017; and (iii) our management’s discussion and analysis of financial condition and results of operations included in our 2016 Form 10-K. This discussion includes forward-looking statements that are subject to risk and uncertainties. Actual results may differ substantially from the statements we make in this section due to a number of factors that are discussed in “Forward-Looking Statements” herein and “Part I – Item 1A. Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2016.
References to “we,” “us,” “our” and the “Company” shall mean U.S. Physical Therapy, Inc. and its subsidiaries.
EXECUTIVE SUMMARY
Our Business
We operate outpatient physical therapy clinics that provide preventive and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers. As of June 30, 2017, we operated 566 clinics in 41 states.
We also manage physical therapy facilities for third parties, primarily physicians, with 27 third-party facilities under management as of June 30, 2017.
During the six months of 2017 and the year ended 2016, we acquired the following clinic groups:
| Date 2017 | % Interest Acquired | Number of Clinics | |
|---|---|---|---|
| June 2017 Acquisition | June 30 | 60% | 9 |
| May 2017 Acquisition | May 31 | 70% | 4 |
| January 2017 Acquisition | January 1 | 70% | 17 |
| 2016 | |||
| February 2016 Acquisition | February 29 | 55% | 8 |
| November 2016 Acquisition | November 30 | 60% | 12 |
On June 30, 2017, we acquired a 60% interest in a nine-clinic physical therapy practice. The purchase price for the 60% interest was $15.8 million in cash and $0.5 million in a seller note that is payable in two principal installments totaling $250,000 each, plus accrued interest, in June 2018 and 2019. On May 31, 2017 we also acquired 70% interest in a four-clinic physical therapy practice. The purchase price for the 70% interest was $2.3 million in cash and $250,000 in a seller note that is payable in two principal installments totaling $125,000 each, plus accrued interest, in May 2018 and 2019. On January 1, 2017, we acquired a 70% interest in a seventeen-clinic physical therapy practice. The purchase price for the 70% interest was $10.7 million in cash and $0.5 million in a seller note that is payable in two principal installments totaling $250,000 each, plus accrued interest, in January 2018 and 2019.
In addition to the above clinic groups, we acquired a 55% interest in a company which is a leading provider of workforce performance solutions. Services provided include onsite injury prevention and rehabilitation, performance optimization and ergonomic assessments. The majority of these services are contracted with and paid for directly by employers including a number of Fortune 500 companies. Other clients include large insurers and their contractors. The purchase price for the 55% interest was $6.2 million in cash and $0.4 million in a seller note that is payable, principal plus accrued interest, in September 2018.
On November 30, 2016, we acquired a 60% interest in a 12 clinic physical therapy practice. The purchase price for the 60% interest was $11.0 million in cash and $0.5 million in a seller note that is payable in two principal installments of $250,000 each, plus accrued interest, in November 2017 and 2018. On February 29, 2016, we acquired a 55% interest in an eight-clinic physical therapy practice. The purchase price for the 55% interest was $13.2 million in cash and $0.5 million in a seller note that is payable in two principal installments totaling $250,000 each, plus accrued interest, one of which was paid in February 2017 and one of which is due in February 2018. In addition, we acquired a single clinic practice in June 2016 for $50,000.
Selected Operating and Financial Data
The following table presents selected operating and financial data that we believe are key indicators of our operating performance.
| For the Three Months Ended June 30, 2017 | June 30, 2016 | For the Six Months Ended June 30, 2017 | June 30, 2016 | |
|---|---|---|---|---|
| Number of clinics, at the end of period | 566 | 516 | 566 | 516 |
| Working Days | 64 | 64 | 128 | 128 |
| Average visits per day per clinic | 25.8 | 25.6 | 25.5 | 25.2 |
| Total patient visits | 923,624 | 840,020 | 1,815,254 | 1,648,301 |
| Net patient revenue per visit | $105.73 | $105.27 | $105.39 | $105.25 |
RESULTS OF OPERATIONS
Three Months Ended June 30, 2017 Compared to the Three Months Ended June 30, 2016
- For the quarter ended June 30, 2017 (the “2017 Second Quarter”), our net income attributable to common shareholders prior to interest expense – mandatorily redeemable non-controlling interests – change in redemption value and costs related to restatement of financials, both net of tax (“operating results”), a non-generally accepted accounting principles (“non-GAAP”) measure, was $7.4 million as compared to $7.2 million in the comparable 2016 period (the “2016 Second Quarter”). Diluted earnings per share from operating results was $0.59 in the 2017 period as compared to $0.57 in the 2016 period.
- For the quarter ended June 30, 2017, our net income attributable to its shareholders, in accordance with generally accepted accounting principles (“GAAP”), was $4.9 million, or $0.39 per diluted share, as compared to $6.0 million, or $0.48 per diluted share, for the 2016 period. See schedule below for a reconciliation of net income attributable to our shareholders to operating results.
Operating results is defined as USPH’s net income attributable to common shareholders prior to interest expense – mandatorily redeemable non-controlling interests – change in redemption value and costs related to the restatement of financial statements, both net of tax. Management uses operating results, which eliminates this current non-cash item that can be subject to volatility and unusual costs, as one of the principal measures to evaluate and monitor financial performance period over period. Management believes that operating results is useful information for investors to use in comparing the Company's period-to-period results as well as for comparing with other similar businesses since most do not have mandatorily redeemable instruments and therefore have different liability and equity structures.
| Three Months Ended June 30, 2017 | 2016 (as restated) | |
|---|---|---|
| Net income attributable to USPH shareholders | $4,941 | $6,012 |
| Adjustments: | ||
| Interest expense MRNCI * - change in redemption value | 3,923 | 1,931 |
| Costs related to restatement of financials - legal and accounting | 177 | - |
| Tax effect at statutory rate (federal and state) of 39.25% | (1,609) | (758) |
| Operating results | $7,432 | $7,185 |
| Basic and diluted net income attributable to USPH shareholders per share | $0.39 | $0.48 |
| Basic and diluted operating results per share | $0.59 | $0.57 |
| Shares used in computation: | ||
| Basic and diluted | 12,579 | 12,511 |
*Mandatorily redeemable non-controlling interest
Revenues
- Net revenues increased $13.9 million or 15.3% from $90.4 million in the second quarter of 2016 to $104.3 million in the second quarter of 2017, primarily due to a 10.0% increase in net patient revenues from the physical therapy operations and a full quarter of revenues from the workforce performance solutions business acquired in March 2017 (see above discussion under “Executive Summary”).
- Net patient revenues from physical therapy operations increased approximately $9.3 million to $97.7 million in the 2017 period from $88.4 million in the 2016 period due to an increase in total patient visits of 10.0% from 840,000 to 923,700 plus an increase in average net patient revenue per visit to $105.73 from $105.27. Of the $9.3 million increase, $7.7 million was related to clinics opened or acquired in the past 12 months. For the 2017 and 2016 period, revenues from management contracts was $1.6 million for each period. The revenues from the recently acquired workforce performance solutions business was $4.4 million for the second quarter of 2017. Other revenue was $0.6 million for the 2017 period and $0.4 million for the 2016 period.
Net patient revenues are based on established billing rates less allowances and discounts for patients covered by contractual programs and workers’ compensation. Net patient revenues are determined after contractual and other adjustments relating to patient discounts from certain payors. Payments received under contractual programs and workers’ compensation are based on predetermined rates and are generally less than the established billing rates.
Clinic Operating Costs
Total clinic operating costs were $79.7 million, or 76.5% of net revenues, in the second quarter of 2017 as compared to $67.4 million, or 74.5% of net revenues, in the 2016 period. The increase was attributable to $6.7 million in operating costs related to new clinics opened or acquired in the past 12 months (“New Clinics”), $3.7 million related to the addition of the workforce performance solutions business and $1.9 million related to clinics opened or acquired prior to July 1, 2016 (“Mature Clinics”). Each component of clinic operating costs is discussed below:
Clinic Operating Costs—Salaries and Related Costs
Salaries and related costs increased to $58.8 million for the 2017 Second Quarter from $48.8 million for the 2016 Second Quarter, an increase of $10.0 million, or 20.4%. Salaries and related costs for New Clinics and the workforce performance solutions business amounted to $8.0 million for the 2017 Second Quarter. Salaries and related costs for Mature Clinics increased by $2.0 million for the 2017 Second Quarter, of which $0.5 million of the $2.0 million increase related to a full quarter of activity in 2017 for clinics opened or acquired in the first six months of 2016, as compared to the 2016 Second Quarter. Salaries and related costs as a percentage of net revenues were 56.4% for the 2017 Second Quarter and 54.0% for the 2016 Second Quarter.
Clinic Operating Costs—Rent, Clinic Supplies, Contract Labor and Other Costs
Rent, clinic supplies, contract labor and other were $20.0 million for the 2017 Second Quarter and $17.5 million for the 2016 Second Quarter. For New Clinics and the workforce performance solutions business, rent, clinic supplies, contract labor and other amounted to $2.4 million for the 2017 Second Quarter. For Mature Clinics, rent, clinic supplies, contract labor and other remained relatively the same in the 2017 Second Quarter compared to the 2016 Second Quarter. Rent, clinic supplies, contract labor and other as a percentage of net revenues was 19.2% for the 2017 Second Quarter and 19.4% for the 2016 Second Quarter.
Clinic Operating Costs—Provision for Doubtful Accounts
The provision for doubtful accounts was $0.9 million for the 2017 Second Quarter and $1.0 million for the 2016 Second Quarter. The provision for doubtful accounts for patient accounts receivable as a percentage of net patient revenues was 0.9% for the 2017 Second Quarter and 1.1% for the 2016 Second Quarter.
Our provision for doubtful accounts for patient accounts receivable as a percentage of total patient accounts receivable was 3.8% at June 30, 2017, as compared to 4.4% at December 31, 2016. Our day’s sales outstanding were 37 days at June 30, 2017 and 36 days at December 31, 2016.
Gross Margin
The gross margin for the 2017 Second Quarter was $24.5 million, or 23.5% of revenue, as compared to $23.0 million, or 25.5% of revenue, for the 2016 Second Quarter. The gross margin for the Company’s physical therapy clinics was 24.2% in the recent quarter as compared to 25.6% a year earlier. The gross margin on management contracts was 7.4% in the 2017 Second Quarter as compared to 22.5% in the 2016 Second Quarter. The gross margin for the recently acquired workforce performance solutions business was 15.0%.
Corporate Office Costs
Corporate office costs, consisting primarily of salaries and benefits of corporate office personnel, rent, insurance costs, depreciation and amortization, travel, legal, accounting, professional, and recruiting fees, were $8.9 million for the 2017 Second Quarter and $8.0 million for the 2016 Second Quarter. Included in the corporate office costs in the second quarter of 2017 was $177,000 of charges related to the legal and accounting costs for the restatement of our financial statements. As a percentage of net revenues, corporate office costs were 8.5% for the 2017 Second Quarter and 8.9% for the 2016 Second Quarter.
Interest Expense mandatorily redeemable non-controlling interest – change in redemption value
Interest Expense mandatorily redeemable non-controlling interest – change in redemption value increased to $3.9 million in the 2017 Second Quarter from $1.9 million in the 2016 Second Quarter. The change in redemption value for acquired partnerships is based on the redemption amount (which is derived from a formula based on a specified multiple times the underlying business’ trailing twelve months of earnings before interest, taxes, depreciation, amortization and our internal management fee) at the end of the reporting period compared to the end of the previous period. This change is directly related to an increase in the profitability and underlying value of the Company’s partnerships.
Interest Expense mandatorily redeemable non-controlling interest – earnings allocation
Interest expense – mandatorily redeemable non-controlling interest – earnings allocable, which represent the portion of earnings allocable to the holders of mandatorily redeemable non-controlling interest, increased to $1.8 million in the 2017 Second Quarter from $1.3 million in the 2016 Second Quarter.
Interest Expense – debt and other
Interest expense increased to $516,000 in the 2017 Second Quarter compared to $320,000 in the 2016 Second Quarter due to a higher average balance outstanding under our Amended Credit Agreement. At June 30, 2017, $69.0 million was outstanding under our Amended Credit Agreement. See “—Liquidity and Capital Resources” below for a discussion of the terms of our Amended Credit Agreement.
Provision for Income Taxes
The provision for income taxes for the 2017 Second Quarter was $3.1 million and for the 2016 Second Quarter was $3.8 million. The provision for income taxes as a percentage of income before taxes less net income attributable to non-controlling interest was 38.4% in the 2017 Second Quarter and 38.7% in the 2016 Second Quarter. Included in the both Second Quarter of 2017 and quarter of 2016 was an excess tax benefit, which had the effect of reducing the effective tax rate, of $0.1 million related to accounting for stock compensation.
Non-controlling Interests
Net income attributable to non-controlling interests was $1.4 million for the 2017 Second Quarter and $1.7 million for the 2016 Second Quarter.
Six Months Ended June 30, 2017 Compared to the Six Months Ended June 30, 2016
- For the six months ended June 30, 2017, our operating results, a non-GAAP measure, were $14.0 million as compared to $13.0 million in the comparable 2016 period. Diluted earnings per share from operating results was $1.11 in the 2017 period as compared to $1.04 in the 2016 period.
- For the six months ended June 30, 2017, our net income attributable to its shareholders, in accordance with GAAP, was $9.8 million, or $0.78 per diluted share, as compared to $10.5 million, or $0.84 per diluted share, for the 2016 period. See schedule below for a reconciliation of net income attributable to our shareholders to operating results.
Operating results is defined as USPH’s net income attributable to common shareholders prior to interest expense – mandatorily redeemable non-controlling interests – change in redemption value and costs related to the restatement of financial statements, both net of tax. Management uses operating results, which eliminates this current non-cash item that can be subject to volatility and unusual costs, as one of the principal measures to evaluate and monitor financial performance period over period. Management believes that operating results is useful information for investors to use in comparing the Company's period-to-period results as well as for comparing with other similar businesses since most do not have mandatorily redeemable instruments and therefore have different liability and equity structures.
| For Six Months Ended June 30, 2017 | 2016 (as restated) | |
|---|---|---|
| Net income attributable to USPH shareholders | $9,757 | $10,500 |
| Adjustments: | ||
| Interest expense MRNCI * - change in redemption value | 6,592 | 4,122 |
| Costs related to restatement of financials - legal and accounting | 312 | - |
| Tax effect at statutory rate (federal and state) of 39.25% | (2,710) | (1,618) |
| Operating results | $13,951 | $13,004 |
| Basic and diluted net income attributable to USPH shareholders per share | $0.78 | $0.84 |
| Basic and diluted operating results per share | $1.11 | $1.04 |
| Shares used in computation: | ||
| Basic and diluted | 12,553 | 12,480 |
*Mandatorily redeemable non-controlling interests
Revenues
- Net revenues increased $24.5 million or 13.8% from $177.3 million in the 2016 First Six Months to $201.8 million in the 2017 First Six Months, primarily due to a 10.1% increase in net patient visits from 1,648,300 to 1,815,300, higher revenues from management contracts due to an increase in the number of facilities managed by the Company and revenues from the workforce performance solutions business acquired in March 2017.
- Net patient revenues from physical therapy operations increased approximately $17.8 million to $191.3 million in the 2017 period from $173.5 million in the 2016 period due to an increase in total patient visits of 10.1% from 1,648,300 to 1,815,254 and slight increase in average net patient revenue per visit to $105.39 from $105.25. Of the $17.8 million increase, $14.5 related to New Clinics. For the 2017 First Six Months, revenues from management contracts was $3.5 million as compared to $2.9 million for the 2016 first six months. The revenues from the recently acquired workforce performance solutions business was $5.9 million for the four months of operations in 2017. Other revenue was $1.1 million for the 2017 First Six Months and $0.9 million for the 2016 First Six Months.
Net patient revenues are based on established billing rates less allowances and discounts for patients covered by contractual programs and workers’ compensation. Net patient revenues are determined after contractual and other adjustments relating to patient discounts from certain payors. Payments received under contractual programs and workers’ compensation are based on predetermined rates and are generally less than the established billing rates.
Clinic Operating Costs
Total clinic operating costs were $156.5 million, or 77.6% of net revenues, for the 2017 First Six Months as compared to $133.8 million, or 75.4% of net revenues, for the 2016 First Six Months. The increase was attributable to $12.8 million in operating costs related to New Clinics, an additional $2.7 million related to a full six months of activity in 2017 for clinics opened or acquired in the first six months of 2016 and $5.0 million related to the addition of the workforce performance solutions business. Each component of clinic operating costs is discussed below:
Clinic Operating Costs—Salaries and Related Costs
Salaries and related costs increased to $114.6 million for the 2017 First Six Months from $96.6 million for the 2016 First Six Months, an increase of $18.0 million, or 18.6%. Salaries and related costs for New Clinics and the workforce performance solutions business amounted to $13.5 million for the 2017 First Six Months. Salaries and related costs for Mature Clinics increased by $4.5 million for the 2017 First Six Months, primarily related to $1.9 million for a full quarter of activity in 2017 for clinics opened or acquired in the first six months of 2016, as compared to the 2016 First Six Months. Salaries and related costs as a percentage of net revenues were 56.8% for the 2017 First Six Months and 54.5% for the 2016 First Six Months.
Clinic Operating Costs—Rent, Clinic Supplies, Contract Labor and Other Costs
Rent, clinic supplies, contract labor and other were $40.1 million for the 2017 First Six Months and $35.1 million for the 2016 First Six Months. For New Clinics and the workforce performance solutions business, rent, clinic supplies, contract labor and other amounted to $2.8 million for the 2017 First Six Months. For Mature Clinics, rent, clinic supplies, contract labor and other increased by $0.9 million in the 2017 First Six Months compared to the 2016 First Six Months. The $0.9 million increase related to a full quarter of activity in 2017 for clinics opened or acquired in the first six months of 2016, as compared to the 2016 First Six Months. For clinics opened or acquired prior to 2016, rent, clinic supplies, contract labor and other remained the same for the two six month periods. Rent, clinic supplies, contract labor and other as a percentage of net revenues was 19.9% for the 2017 First Six Months and 19.8% for the 2016 First Six Months.
Clinic Operating Costs—Provision for Doubtful Accounts
The provision for doubtful accounts was $1.8 million for the 2017 First Six Months and $2.0 million for the 2016 First Six Months. The provision for doubtful accounts for patient accounts receivable as a percentage of net patient revenues was 0.9% for the 2017 First Six Months and 1.2% for the 2016 First Six Months.
Our provision for doubtful accounts for patient accounts receivable as a percentage of total patient accounts receivable was 3.8% at June 30, 2017, as compared to 4.4% at December 31, 2016. Our day’s sales outstanding were 37 days at June 30, 2017 and 36 days at December 31, 2016.
Gross Margin
The gross margin for the 2017 First Six Months was $45.3 million, or 22.4% of revenue, as compared to $43.6 million, or 24.6% of revenue, for the 2016 First Six Months. The gross margin for the Company’s physical therapy clinics was 22.9% in the recent quarter as compared to 24.6% a year earlier. The gross margin on management contracts was 11.3% in the 2017 First Six Months as compared to 21.2% in the 2016 First Six Months. The gross margin for the recently acquired workforce performance solutions business was 14.8%.
Corporate Office Costs
Corporate office costs, consisting primarily of salaries and benefits of corporate office personnel, rent, insurance costs, depreciation and amortization, travel, legal, accounting, professional, and recruiting fees, were $17.4 million for the 2017 First Six Months and $17.0 million for the 2016 First Six Months. Included in the corporate office costs in the first six months of 2017 was $312,000 of charges related to the legal and accounting costs for the restatement of our financial statements. As a percentage of net revenues, corporate office costs were 8.6% for the 2017 First Six Months and 9.6% for the 2016 First Six Months.
Interest Expense mandatorily redeemable non-controlling interest – change in redemption value
Interest Expense mandatorily redeemable non-controlling interest – change in redemption value increased to $6.6 million in the 2017 First Six Months from $4.1 million in the 2016 First Six Months. The change in redemption value for acquired partnerships is based on the redemption amount (which is derived from a formula based on a specified multiple times the underlying business’ trailing twelve months of earnings before interest, taxes, depreciation, amortization and our internal management fee) at the end of the reporting period compared to the end of the previous period. This is a non-cash item and is directly related to the increase in the profitability and underlying value of the Company’s partnerships.
Interest Expense mandatorily redeemable non-controlling interest – earnings allocation
Interest expense – mandatorily redeemable non-controlling interest – earnings allocable, which represent the portion of earnings allocable to the holders of mandatorily redeemable non-controlling interest, increased to $3.1 million in the 2017 First Six Months from $2.2 million in the 2016 First Six Months.
Interest Expense – debt and other
Interest expense increased to $931,000 in the 2017 First Six Months compared to $628,000 in the 2016 First Six Months due to a higher average balance outstanding under our Amended Credit Agreement. At June 30, 2017, $69.0 million was outstanding under our Amended Credit Agreement. See “—Liquidity and Capital Resources” below for a discussion of the terms of our Amended Credit Agreement.
Provision for Income Taxes
The provision for income taxes for the 2017 First Six Months was $4.9 million and for the 2016 First Six Months was $6.0 million. The provision for income taxes as a percentage of income before taxes less net income attributable to non-controlling interest was 33.4% in the 2017 First Six Months and 36.3% in the 2016 First Six Months. Included in the 2017 First Six Months was an excess tax benefit, which had the effect of reducing the effective tax rate, of $0.9 million related to accounting for stock compensation as compared to $0.6 million in the first six months of 2016.
Non-controlling Interests
Net income attributable to non-controlling interests was $2.7 million for the 2017 First Six Months and $3.1 million for the 2016 First Six Months.
LIQUIDITY AND CAPITAL RESOURCES
We believe that our business is generating sufficient cash flow from operations to allow us to meet our short-term and long-term cash requirements, other than those with respect to future acquisitions. At June 30, 2017 and December 31, 2016, we had $20.2 million and $20.0 million, respectively, in cash. Although the start-up costs associated with opening new clinics and our planned capital expenditures are significant, we believe that our cash and unused availability under our revolving credit agreement are sufficient to fund the working capital needs of our operating subsidiaries, future clinic development and acquisitions and investments through at least June 2018. Significant acquisitions would likely require additional financing.
Effective December 5, 2013, we entered into an Amended and Restated Credit Agreement with a commitment for a $125.0 million revolving credit facility with a maturity date of November 30, 2018. This agreement was amended in August 2015, January 2016 and March 2017 (hereafter referred to as “Amended Credit Agreement”). The Amended Credit Agreement is unsecured and has loan covenants, including requirements that the Company comply with a consolidated fixed charge coverage ratio and consolidated leverage ratio. Proceeds from the Amended Credit Agreement may be used for working capital, acquisitions, purchases of the Company’s common stock, dividend payments to the Company’s common stockholders, capital expenditures and other corporate purposes. The pricing grid which is based on the Company’s consolidated leverage ratio with the applicable spread over LIBOR ranging from 1.5% to 2.5% or the applicable spread over the Base Rate ranging from 0.1% to 1%. Fees under the Amended Credit Agreement include an unused commitment fee ranging from 0.1% to 0.25% depending on the Company’s consolidated leverage ratio and the amount of funds outstanding under the Amended Credit Agreement. On June 30, 2017, $69.0 million was outstanding under our Amended Credit Agreement resulting in $56.0 million of availability. As of the date of this Quarterly Report, we were in compliance with all of the covenants thereunder.
Cash and cash equivalents increased by $0.2 million from December 31, 2016 to June 30, 2017. During the six months ended June 30, 2017, $22.2 million was provided by operations and $23.0 million from net proceeds drawn on the line of credit provided in our Amended Credit Agreement. The major uses of cash for investing and financing activities included: purchase of businesses ($33.7 million), purchases of fixed assets ($3.2 million), distributions to non-controlling interests ($2.7 million), cash dividends to our common shareholders ($2.5 million), payments to settle mandatorily redeemable non-controlling interests ($2.2 million), and payments on notes payable ($0.8 million).
On January 1, 2017, we acquired a 70% interest in a seventeen-clinic physical therapy practice. The purchase price for the 70% interest was $10.7 million in cash and $0.5 million in a seller note that is payable in two principal installments totaling $250,000 each, plus accrued interest, in January 2018 and 2019.
In March 2017, we acquired a 55% interest in a company which is a leading provider of workforce performance solutions. Services provided include onsite injury prevention and rehabilitation, performance optimization and ergonomic assessments. The majority of these services are contracted with and paid for directly by employers including a number of Fortune 500 companies. Other clients include large insurers and their contractors. The purchase price for the 55% interest was $6.2 million in cash and $0.4 million in a seller note that is payable, principal plus accrued interest, in September 2018.
On May 31, 2017, we acquired a 70% interest in a four-clinic physical therapy practice. The purchase price for the 70% interest was $2.3 million in cash and $250,000 in a seller note that is payable in two principal installments totaling $125,000 each, plus accrued interest, in May 2018 and 2019.
On June 30, 2017, we acquired a 60% interest in a nine-clinic physical therapy practice. The purchase price for the 60% interest was $15.8 million in cash and $0.5 million in a seller note that is payable in two principal installments totaling $250,000 each, plus accrued interest, in June 2018 and 2019.
On November 30, 2016, we acquired a 60% interest in a 12 clinic physical therapy practice. The purchase price for the 60% interest was $11.0 million in cash and $0.5 million in a seller note that is payable in two principal installments of $250,000 each, plus accrued interest, in November 2017 and 2018. On February 29, 2016, we acquired a 55% interest in an eight-clinic physical therapy practice. The purchase price for the 55% interest was $13.2 million in cash and $0.5 million in a seller note that is payable in two principal installments totaling $250,000 each, plus accrued interest, one of which was paid in February 2017 and one of which is payable in February 2018. In addition, we acquired a single clinic practice in June 2016 for $50,000.
Historically, we have generated sufficient cash from operations to fund our development activities and to cover operational needs. We plan to continue developing new clinics and making additional acquisitions. We also from time to time purchase the non-controlling interests in our Clinic Partnerships. Generally, any acquisition or purchase of non-controlling interests is expected to be accomplished using a combination of cash and financing. Any large acquisition would likely require financing.
We make reasonable and appropriate efforts to collect accounts receivable, including applicable deductible and co-payment amounts, in a consistent manner for all payor types. Claims are submitted to payors daily, weekly or monthly in accordance with our policy or payor’s requirements. When possible, we submit our claims electronically. The collection process is time consuming and typically involves the submission of claims to multiple payors whose payment of claims may be dependent upon the payment of another payor. Claims under litigation and vehicular incidents can take a year or longer to collect. Medicare and other payor claims relating to new clinics awaiting Medicare Rehab Agency status approval initially may not be submitted for six months or more. When all reasonable internal collection efforts have been exhausted, accounts are written off prior to sending them to outside collection firms. With managed care, commercial health plans and self-pay payor type receivables, the write-off generally occurs after the account receivable has been outstanding for at least 120 days.
We generally enter into various notes payable as a means of financing our acquisitions. Our outstanding notes payable as of June 30, 2017 relate to certain of the acquisitions of businesses, purchases of non-controlling interests and settlements of mandatorily redeemable non-controlling interests that occurred in 2015 through June 2017. Typically, the notes are payable in equal annual installments of principal over two years plus any accrued and unpaid interest. Interest accrues at various interest rates ranging from 3.25% to 4.0% per annum, subject to adjustment. At June 30, 2017, the balance on these notes payable was $6.7 million. In addition, we assumed leases with remaining terms of 1 month to 6 years for the operating facilities.
In conjunction with the above mentioned acquisitions, in the event that a limited minority partner’s employment ceases at any time after a specified date that is between three and five years from the acquisition date, we have agreed to repurchase that individual’s non-controlling interest at a predetermined multiple of earnings before interest and taxes.
As of June 30, 2017, we have accrued $4.4 million related to credit balances due to patients and payors. This amount is expected to be paid in the next twelve months.
From September 2001 through December 31, 2008, our Board of Directors (“Board”) authorized us to purchase, in the open market or in privately negotiated transactions, up to 2,250,000 shares of our common stock. In March 2009, the Board authorized the repurchase of up to 10% or approximately 1,200,000 shares of our common stock (“March 2009 Authorization”). Our Amended Credit Agreement permits share repurchases of up to $15,000,000, subject to compliance with covenants. We are required to retire shares purchased under the March 2009 Authorization.
There is no expiration date for the share repurchase program. As of June 30, 2017, there are currently an additional estimated 248,344 shares (based on the closing price of $60.40 on June 30, 2017) that may be purchased from time to time in the open market or private transactions depending on price, availability and our cash position. We did not purchase any shares of our common stock during the six months ended June 30, 2017.
FACTORS AFFECTING FUTURE RESULTS
The risks related to our business and operations include:
- cost, risks and uncertainties associated with the Company’s recent restatement of its prior financial statements due to the correction of its accounting methodology for redeemable noncontrolling partnership interests, and including any pending and future claims or proceedings relating to such matters;
- changes in Medicare rules and guidelines and reimbursement or failure of our clinics to maintain their Medicare certification or enrollment status;
- revenue we receive from Medicare and Medicaid being subject to potential retroactive reduction;
- business and regulatory conditions including federal and state regulations;
- governmental and other third party payor inspections, reviews, investigations and audits;
- compliance with federal and state laws and regulations relating to the privacy of individually identifiable patient information, and associated fines and penalties for failure to comply;
- legal actions, which could subject us to increased operating costs and uninsured liabilities;
- changes in reimbursement rates or payment methods from third party payors including government agencies and deductibles and co-pays owed by patients;
- revenue and earnings expectations;
- general economic conditions;
- availability and cost of qualified physical therapists;
- personnel productivity and retaining key personnel;
- competitive, economic or reimbursement conditions in our markets which may require us to reorganize or close certain clinics and thereby incur losses and/or closure costs including the possible write-down or write-off of goodwill and other intangible assets;
- acquisitions, purchase of non-controlling interests (minority interests) and the successful integration of the operations of the acquired businesses;
- our ability to design and maintain effective internal control over financial reporting and remediate the material weakness in internal control over financial reporting related to our accounting for redeemable non-controlling partnership interests;
- maintaining necessary insurance coverage;
- availability, terms, and use of capital; and
- weather and other seasonal factors.
See Risk Factors in Item 1A of our Annual Report on Form 10-K.
Forward-Looking Statements
We make statements in this report that are considered to be forward-looking statements within the meaning given such term under Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements contain forward-looking information relating to the financial condition, results of operations, plans, objectives, future performance and business of our Company. These statements (often using words such as “believes”, “expects”, “intends”, “plans”, “appear”, “should” and similar words) involve risks and uncertainties that could cause actual results to differ materially from those we project. Included among such statements are those relating to opening new clinics, availability of personnel and the reimbursement environment. The forward-looking statements are based on our current views and assumptions and actual results could differ materially from those anticipated in such forward-looking statements as a result of certain risks, uncertainties, and factors, which include, but are not limited to:
Many factors are beyond our control. Given these uncertainties, you should not place undue reliance on our forward-looking statements. Please see our periodic reports filed with the Securities and Exchange Commission (the “SEC”) for more information on these factors. Our forward-looking statements represent our estimates and assumptions only as of the date of this report. Except as required by law, we are under no obligation to update any forward-looking statement, regardless of the reason the statement is no longer accurate.
- cost, risks and uncertainties associated with the Company’s recent restatement of its prior financial statements due to the correction of its accounting methodology for redeemable noncontrolling partnership interests, and including any pending and future claims or proceedings relating to such matters;
- changes as the result of government enacted national healthcare reform;
- changes in Medicare rules and guidelines and reimbursement or failure of our clinics to maintain their Medicare certification status;
- revenue we receive from Medicare and Medicaid being subject to potential retroactive reduction;
- business and regulatory conditions including federal and state regulations;
- governmental and other third party payor inspections, reviews, investigations and audits;
- compliance with federal and state laws and regulations relating to the privacy of individually identifiable patient information, and associated fines and penalties for failure to comply;
- legal actions; which could subject us to increased operating costs and uninsured liabilities;
- changes in reimbursement rates or payment methods from third party payors including government agencies and deductibles and co-pays owed by patients;
- revenue and earnings expectations;
- general economic conditions;
- availability and cost of qualified physical therapists;
- personnel productivity and retaining key personnel;
- competitive, economic or reimbursement conditions in our markets which may require us to reorganize or close certain clinics and thereby incur losses and/or closure costs including the possible write-down or write-off of goodwill and other intangible assets;
- acquisitions, purchase of non-controlling interests (minority interests) and the successful integration of the operations of the acquired businesses;
- maintaining adequate internal controls;
- maintaining necessary insurance coverage;
- our ability to design and maintain effective internal control over financial reporting and remediate the material weakness in internal control over financial reporting related to our accounting for redeemable non-controlling partnership interests;
- availability, terms, and use of capital; and
- weather and other seasonal factors.
Many factors are beyond our control. Given these uncertainties, you should not place undue reliance on our forward-looking statements. Please see the other sections of this report and our other periodic reports filed with the Securities and Exchange Commission (the “SEC”) for more information on these factors. Our forward-looking statements represent our estimates and assumptions only as of the date of this report. Except as required by law, we are under no obligation to update any forward-looking statement, regardless of the reason the statement may no longer be accurate.
Market risk
As filed, 581 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
We do not maintain any derivative instruments, interest rate swap arrangements, hedging contracts, futures contracts or the like. Our primary market risk exposure is the changes in interest rates obtainable on our Amended Credit Agreement. The interest on our Amended Credit Agreement is based on a variable rate. At June 30, 2017, $69.0 million was outstanding under our Amended Credit Agreement. Based on the balance of the Amended Credit Agreement at June 30, 2017, any change in the interest rate of 1% would yield a decrease or increase in annual interest expense of $690,000.
Controls and procedures
As filed, 4,246 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
(a) Evaluation of Disclosure Controls and Procedures
Our management, including our Chief Executive Officer and Chief Financial Officer, has conducted an evaluation of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) promulgated under the Exchange Act) as of the end of the period covered by this report. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as a result of the material weakness in our internal control over financial reporting discussed in the Company’s Annual Report on Form 10-K, for the year ended December 31, 2016, our disclosure controls and procedures were not effective in ensuring that the information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the SEC and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding disclosure.
(b) Previously Reported Material Weaknesses in Internal Control over Financial Reporting
As discussed in the Company’s Annual Report on Form 10-K, for the year ended December 31, 2016, Management conducted an assessment of the effectiveness of our internal control over financial reporting as of December 31, 2016. Based on this assessment, management concluded that our internal control over financial reporting was not effective as of December 31, 2016 as a result of the material weakness discussed below.
Redeemable non-controlling interests – We did not properly account for redeemable non-controlling interests. The Company’s business combination / purchase accounting controls relating to our accounting for redeemable non-controlling interests were not designed effectively to ensure that we correctly interpreted and applied technical accounting requirements concerning the classification of such interests on our consolidated financial statements.
Changes in Internal Control Over Financial Reporting
Other than the material weakness described above, there have been no changes in our internal control over financial reporting during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Subsequent to the period covered by this report we implemented the following changes to our internal control over financial reporting process as it relates to redeemable non-controlling interests to begin to remediate the material weakness.
- The Assistant Controller reviews the language and terms of any new standard limited partnership agreement created by the Company’s legal department. The sections which contain language having a potential accounting impact are identified and listed on the “Accounting Considerations for Limited Partnership Agreements” checklist.
- For each new limited partnership agreement executed by the company’s legal department, the Assistant Controller obtains a completed and signed “Accounting Considerations for Limited Partnership Agreements” checklist from the company’s General Counsel indicating if the language having a potential accounting impact denoted on the checklist referenced above has changed.
- If a change is denoted on the “Accounting Considerations for Limited Partnership Agreements” checklist, the Corporate or Assistant Controller will review the agreement and research the changed language for accounting and disclosure implications. If the nature of the language is such that interpretation is subjective, and Management does not believe they have the technical experience in that transaction type, research will include seeking outside counsel from a third party accounting expert, such as a consulting or accounting firm. A memo is drafted with the appropriate facts and resolution and approved by the Corporate Controller and Chief Financial Officer.
Management believes the new process and controls stated above are precise enough to identify and prevent the type of accounting error which occurred related to limited partnership agreements.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Gross profit | 3 months2017-04-01 to 2017-06-30 | $24.5m | us-gaap:GrossProfit |
| Gross profit | 6 months2017-01-01 to 2017-06-30 | $45.3m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months2017-04-01 to 2017-06-30 | $8.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2017-01-01 to 2017-06-30 | $17.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2017-04-01 to 2017-06-30 | $15.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2017-01-01 to 2017-06-30 | $27.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2017-04-01 to 2017-06-30 | $6.2m | us-gaap:InterestExpense |
| Interest expense | 6 months2017-01-01 to 2017-06-30 | $10.6m | us-gaap:InterestExpense |
| Income tax | 3 months2017-04-01 to 2017-06-30 | $3.1m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2017-01-01 to 2017-06-30 | $4.9m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2017-04-01 to 2017-06-30 | $4.9m | us-gaap:NetIncomeLoss |
| Net income | 6 months2017-01-01 to 2017-06-30 | $9.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2017-04-01 to 2017-06-30 | $0.39 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months2017-01-01 to 2017-06-30 | $0.78 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted shares (weighted) | 3 months2017-04-01 to 2017-06-30 | 12,579,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2017-01-01 to 2017-06-30 | 12,553,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2017-01-01 to 2017-06-30 | $22.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2017-01-01 to 2017-06-30 | $3.2m | us-gaap:PaymentsToAcquireProductiveAssets |
| Dividends paid | 6 months2017-01-01 to 2017-06-30 | $2.5m | us-gaap:PaymentsOfDividendsCommonStock |
| Cash and equivalents | At period end2017-06-30 | $20.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2017-06-30 | $79.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2017-06-30 | $417.3m | us-gaap:Assets |
| Current liabilities | At period end2017-06-30 | $35.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2017-06-30 | $209.4m | us-gaap:Liabilities |
| Long-term debt | At period end2017-06-30 | $73.4m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2017-06-30 | $2.3m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2017-06-30 | $194.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001140361-17-030329. Last ingested by Listed: Nov 14, 2026, 13:45 ET. Listed shows no prices and gives no investment advice.